- Home
- OTLY vs PRTA Comparison
OTLY vs PRTA Comparison
Compare OTLY & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- PRTA
- Stock Information
- Founded
- OTLY 1994
- PRTA 2012
- Country
- OTLY Sweden
- PRTA Ireland
- Employees
- OTLY N/A
- PRTA N/A
- Industry
- OTLY Packaged Foods
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- PRTA Health Care
- Exchange
- OTLY Nasdaq
- PRTA Nasdaq
- Market Cap
- OTLY 696.2M
- PRTA 802.8M
- IPO Year
- OTLY 2021
- PRTA N/A
- Fundamental
- Price
- OTLY $0.61
- PRTA $14.01
- Analyst Decision
- OTLY Buy
- PRTA Buy
- Analyst Count
- OTLY 3
- PRTA 7
- Target Price
- OTLY $1.27
- PRTA $57.67
- AVG Volume (30 Days)
- OTLY 3.5M
- PRTA 476.3K
- Earning Date
- OTLY 11-07-2024
- PRTA 11-12-2024
- Dividend Yield
- OTLY N/A
- PRTA N/A
- EPS Growth
- OTLY N/A
- PRTA N/A
- EPS
- OTLY N/A
- PRTA N/A
- Revenue
- OTLY $813,471,000.00
- PRTA $133,350,000.00
- Revenue This Year
- OTLY $8.55
- PRTA $60.63
- Revenue Next Year
- OTLY $8.40
- PRTA N/A
- P/E Ratio
- OTLY N/A
- PRTA N/A
- Revenue Growth
- OTLY 5.06
- PRTA N/A
- 52 Week Low
- OTLY $0.60
- PRTA $14.00
- 52 Week High
- OTLY $1.40
- PRTA $41.55
- Technical
- Relative Strength Index (RSI)
- OTLY 30.75
- PRTA 31.91
- Support Level
- OTLY $0.76
- PRTA $17.27
- Resistance Level
- OTLY $0.96
- PRTA $18.60
- Average True Range (ATR)
- OTLY 0.06
- PRTA 1.11
- MACD
- OTLY -0.02
- PRTA -0.15
- Stochastic Oscillator
- OTLY 1.38
- PRTA 0.20
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).